We addressed the question of whether alteration in the HER1, HER3 or HER4 genes or their protein products conveys any prognostic value that is complementary to or independent of HER2 that would allow a more precise rendering of breast cancer patients into subgroups with different clinical outcomes based on HER-receptor analysis. Here, ERBB2 is linked to breast carcinoma.